The AMP-activated protein kinase (AMPK) is a regulator of energy balance at both the cellular and whole-body levels but little is known about the role of AMPK in platelet activation.
Introduction
The AMP-activated protein kinase (AMPK) is a heterotrimeric serine/threonine protein kinase consisting of the catalytic subunit (α) and two regulatory subunits (β and γ) that exist as multiple isoforms and splice variants. Each subunit within the heterotrimeric AMPK complex has a distinct structure and function and their interaction is necessary for the modulation of kinase activity. As its name suggests, the AMPK is activated in many different cell types by increased intracellular concentrations of AMP, and is generally referred to as a "metabolitesensing kinase". Indeed, the AMPK is activated following heat shock, vigorous exercise, hypoxia/ischemia and starvation, and appears to be a metabolic master switch, phosphorylating key target proteins that control flux through different metabolic pathways (for recent detailed review see Steinberg and Kemp 1 ) .
Given that activity is clearly associated with the phosphorylation of the α subunit it was initially assumed that an AMPK kinase (AMPKK) rather than the AMPK itself is activated by AMP. It now seems that AMP binds to the γ subunit, allosterically activating it, so that the α subunit can be phosphorylated at the same time as indirectly inhibiting dephosphorylation. 2 There are several kinases which phosphorylate the AMPKα subunits including the constitutively active tumor suppressor gene product; liver kinase B1 (LKB1), and the Ca 2+ /calmodulin-dependent protein kinase kinase β (CaMKKβ). The activation of the latter following cell stimulation with Ca 2+ ionophores or Ca 2+ elevating agonists, results in the phosphorylation and activation of the AMPK without detectable changes in the AMP/ATP ratio. 3 There are two different AMPKα isoforms that are differentially expressed in different tissues; the α1 isoform predominates in adipose tissue, while the AMPKα2, which determines whole body insulin sensitivity, 4 is expressed in skeletal muscle and to a lesser extent in cardiomyocytes. 5 Whether or not the AMPKαs are preferential substrates for one or more putative AMPKK remains to be clarified.
Platelets play a key role in thrombosis and hemostasis, and although platelet activation is an energy-consuming process, 6;7 surprisingly little is known about the consequences of platelet
For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From activation on the AMPK or the role of the AMPK in the regulation of platelet function. In fact, only one study reports the presence of the kinase in washed human platelets and its activation by insulin. 8 Therefore, the aim of the present study was to determine the role(s) of the AMPKα1 and AMPKα2 in regulating human and murine platelet function.
Materials and Methods

Reagents
The anti-AMPKα1 antibody was generated by Eurogentec (Cologne, Germany), the antibodies against AMPK-α2 and phospho-Thr12-Fyn were from Santa Cruz Biotechnology (Heidelberg, Germany), the antibody recognizing total Fyn antibody was from Abcam (Cambridge, UK) and the antibodies recognizing phospho-Thr172 AMPK, phospho-Ser79
ACC and phospho-Thr189 LKB1 were from Cell Signaling (Frankfurt am Main, Germany).
The phospho-Tyr747 β3-integrin antibody was from Biosource (Karlsruhe, Germany) and the β3-integrin antibody from Epitomics (Biomol, Hamburg, Germany). The antibodies against acetyl-CoA carboxylase (ACC), LKB1 and phospho-threonine Fyn were from Upstate Biotechnology (Biomol, Hamburg, Germany). Recombinant AMPKα1, AMPKα2 and STO-609
were from Calbiochem (Bad Soden, Germany), recombinant Fyn was from Upstate Biotechnology (Biomol, Hamburg, Germany). Thrombin was from Hemochrom Diagnostica GmbH (Essen, Germany), the 3,3'-dihexyloxacarbocyanine iodide (DIOC 6 ), was from Molecular Probes (Karlsruhe, Germany). All other reagents were from Sigma (Steinheim, Germany).
Animals
AMPKα1
-/-(mixed C57BL6 and SV-129 background), and AMPKα2 -/-mice (C57BL6 background) were generated as described. 
Bleeding and re-bleeding time
Mice were anesthetized by intraperitoneal injection of ketamine (80 mg/kg) and xylazine (5 mg/kg) and placed on a heated mat. A one millimeter section of the tail tip was cut and the tail tip immediately immersed in sterile saline at 37°C. The bleeding time i.e. the time between the flows of blood to the cessation of bleeding was recorded. The mice were monitored for an additional 10 minutes and if tail bleeding restarted, incidence was recorded (re-bleeding).
Platelet isolation
Human platelets: Platelets were obtained by centrifugation (900g, 7 min) of platelet-rich plasma, as described. 10 The -free HEPES buffer to a density of 8x10 8 platelets/mL.
Clot retraction
Platelet-rich plasma (adjusted to 3x10 8 platelets/mL for human platelets and 5x10 8 platelets/mL for murine platelets, 300 µL) obtained by centrifugation of whole blood at 250g for 10 minutes, was stimulated with thrombin (0.3 U/mL for human and 1U/mL for murine) in the presence of CaCl 2 (2 mmol/L) and 2 µL erythrocytes to enhance the contrast of the clot.
The clots were allowed to retract for up to 3 hours at 37°C and were photographed at
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Immunoblotting
Washed human or murine platelets were solubilized in Triton X-100 lysis buffer, 50 µg soluble protein (approximately 5x10 7 platelets) were separated by SDS-PAGE and subjected to Western blotting as described. 10 Proteins were visualized by enhanced chemiluminescence using a commercially available kit (Amersham, Freiburg, Germany).
Thrombus formation in a FeCl 3 -induced carotid artery model
Thrombus formation in vivo was assessed as described. 11 Briefly, mice were anesthetized by intraperitoneal injection of ketamine and xylazine and placed on a heated mat. The fluorescent dye DIOC 6 (5 µL of a 100 µmol/L solution/g of body weight) was injected into the jugular vein to allow visualization of the thrombus. Thereafter, a segment of the right carotid artery was exposed and injury was induced by the topical application of FeCl 3 for 2 minutes (Whatmann paper 1 mm 2 soaked with 0.2 µL of 10% FeCl 3 ). The artery was then rinsed with saline and thrombus formation was monitored for 30 minutes by placing the carotid artery under a fluorescence microscope equipped with a camera (AxioScope, Carl Zeiss, Jena, Germany). Fluorescent images were acquired sequentially (1 image/second) and thrombus size was quantified using AxioVision 4.7 imaging software (Carl Zeiss).
In vitro kinase assay. for 40 minutes at 37°C. The reaction was terminated with SDS sample buffer and samples were separated by SDS-PAGE. The gel was dried before being exposed to an X-ray film.
Parallel experiments were performed in the presence of unlabeled ATP and Fyn phosphorylation determined by Western blotting.
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Statistical analysis
Data are expressed as mean ± SEM, and statistical evaluation was performed using Student's t test for unpaired data, one-way analysis of variance (ANOVA) followed by a Bonferroni t test, where appropriate. Values of P<0.05 were considered statistically significant.
Results
Thrombin induces AMPKα phosphorylation via the activation of LKB1
Washed human platelets expressed both the α1 and α2 subunits of the AMPK ( Figure 1A) . A low level of AMPK phosphorylation was detectable in unstimulated platelets but the addition of thrombin (0.03 to 0.3 U/mL) concentration-dependently increased the phosphorylation of the AMPK on Thr172. Phosphorylation is reported to be essential for AMPK activation, 12 and was paralleled by an increase in kinase activity as evidenced by the phosphorylation of the AMPK substrate, ACC ( Figure 1B ).
Several kinases are able to phosphorylate AMPKα subunits, including LKB1 and CaMKKβ. 13 Although the thrombin-induced activation of the AMPK in endothelial cells is dependent on the activation of CaMKKβ, 14 the CaMKK inhibitor STO-609 did not inhibit, but in fact tended to potentiate, the thrombin-induced activation of the AMPK as well as the thrombin-induced aggregation of human platelets (Supplementary Figure I) . However, stimulation of washed human platelets with thrombin markedly increased the phosphorylation of LKB1 indicating that LKB1 is most probably the AMPKK under these conditions ( Figure 2A ). Since the phosphatidylinositol 3-kinase (PI3-K) is known to be activated by thrombin, 15 and has been reported to be upstream of the AMPK in insulin-stimulated platelets, 8 we determined whether or not the PI3-K affects the LKB1-AMPK pathway. Inhibition of the PI3-K using a low concentration of wortmannin (20 nmol/L) prevented the thrombin-induced phosphorylation of LKB1, as well as that of the AMPK and ACC in human platelets ( Figure 2B ). 
AMPKα2 not AMPKα1 regulates clot retraction and thrombus stability
As the pharmacological tools that target the AMPK are not specific 16;17 and there is no possibility to selectively inhibit/downregulate the different α subunits in platelets, we assessed the expression of the AMPK in platelets from wild-type and AMPKα -/-mice. As with washed human platelets, platelets from wild-type mice expressed both AMPKα isoforms ( Figure 4A ). As expected, no AMPKα1 could be detected in platelets from AMPKα1 -/-mice and no AMPKα2 could be detected in platelets from AMPKα2 -/-mice. Consistent with the data obtained using human platelets, thrombin-induced aggregation was attenuated in platelet from AMPKα2 -/-versus AMPKα2 +/+ mice (Supplementary Figure 2) . Moreover, AMPKα2 activation during aggregation was not restricted to the signaling cascade activated by thrombin as collagen-induced aggregation was also significantly inhibited in platelets from AMPKα2 -/-mice (Supplementary Figure 2B) . There was no significant difference in the thrombin-induced aggregation of platelets from AMPKα1 +/+ and AMPKα1 -/-mice (data not shown was observed in platelet-rich plasma from wild-type and AMPKα1 -/-animals ( Figure 4B ), clot retraction in platelet-rich plasma from AMPKα2
-/--deficient mice failed to occur.
There was no significant difference in the tail bleeding times in the animals studied: average bleeding times were 78±8 and 118±28 seconds in AMPKα2 +/+ and AMPKα2 -/-mice, respectively (n=11). However, re-bleeding was more frequently observed in AMPKα2 For
AMPK and the thrombin-induced phosphorylation of β3 integrin
The phosphorylation of the cytoplasmic domain of β3 integrin on Tyr747 is required for stable platelet aggregation and optimal clot retraction.
18-20 Therefore, we determined whether or not the altered function of platelets from AMPKα2 -/-mice could be linked to changes in integrin phosphorylation.
In washed human platelets, thrombin elicited the concentration-dependent tyrosine phosphorylation of β3 integrin; a response markedly attenuated in the presence of compound C ( Figure 5A ). Thrombin also stimulated the tyrosine phosphorylation of β3 integrin in platelets from AMPKα2 +/+ mice but failed to elicit the same response in platelets from their AMPKα2 -/-littermates. The thrombin-induced phosphorylation of β3 integrin was not significantly different in platelets from AMPKα1 +/+ and α1 -/-mice ( Figure 5B ). These data indicate that a β3-phosphorylating tyrosine kinase may be a substrate of the AMPKα2 in platelets.
Several Src family kinases (SFK) can be detected in megakaryocytes and platelets and are thought to be involved in regulating platelet function. 21 Therefore, we determined the consequences of SFK inhibition on β3 integrin phosphorylation. Pretreatment of human platelets with PP2 (30 nmol/L), attenuated the thrombin-induced phosphorylation of β3 integrin ( Figure 6A ) and aggregation; PP2 inhibited the aggregation induced by 0.03 U/mL thrombin by 50.52% (n=4, P<0.05) and that induced by 0.3 U/mL thrombin by 27.31% (n=4,
P<0.05). PP2 did not affect the thrombin-induced phosphorylation of either AMPKα1 or
AMPKα2 (data not shown). As Fyn can phosphorylate β3 integrin and Fyn is itself regulated by phosphorylation on Thr12, 22 we next determined whether or not a link exists between AMPKα2 and Fyn in platelets.
In an in vitro 32 P kinase assay we were able to detect the autophosphorylation of Fyn in the absence of the AMPK but observed a marked increase in phosphorylation in the presence of AMPKα2 ( Figure 6B ). The latter effect was resistant to the SKF inhibitor PP2 but was
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From abrogated by iodotubercidin and compound C indicating the AMPK-dependent phosphorylation of Fyn and not the other way around. Experiments repeated in the absence of radioactive ATP but using a phospho-selective threonine antibody confirmed the threonine phosphorylation of Fyn by AMPKα2 ( Figure 6B ). We were however unable to demonstrate the AMPK-mediated phosphorylation of a purified recombinant Src (data not shown).
We finally assessed the ability of thrombin to elicit the phosphorylation of Fyn on Thr12 in murine platelets and found that, while thrombin induced the phosphorylation of Fyn on Thr12 in platelets from AMPKα2 +/+ mice, there was no detectable phosphorylation of this residue in platelets from AMPKα2 -/-mice ( Figure 6C ). No difference in Fyn phosphorylation was detected in AMPKα1 +/+ and AMPKα1 -/-platelets (data not shown).
Discussion
The results of the present study demonstrate that the α1 and α2 subunits of AMPK are expressed in human and murine platelets. Moreover, platelet activation by thrombin resulted in the phosphorylation of the AMPKK, LKB1, AMPK itself and the AMPK substrate, ACC.
AMPK activation seems to be required for normal platelet responsiveness as pharmacological inhibition of the kinase attenuated platelet aggregation and clot retraction.
Moreover, from studies in AMPKα1 -/-and AMPKα2 -/-mice it seems that the α2 subunit plays a key role in the regulation of platelet function and thrombus stabilization by regulating the Fyn-mediated phosphorylation of β3 integrin.
Platelet activation is an energy consuming process, 6;7 which makes it logical to assume a potentially important role for the AMPK in the regulation of platelet signaling and function.
However, although the AMPK is expressed in platelets, little is known about the predominance of the different α subunits or the mechanisms regulating AMPK activity. We reported previously that platelet stimulation with insulin increased AMPK activity and that AMPK inhibition prevented the anti-aggregatory effects of the hormone 8 but more detailed analysis was hampered by the lack of selectivity of the available inhibitors and appropriate mouse models. We now report that both the AMPKα1 and α2 subunits are expressed in human and murine platelets and that the kinase can be activated by cell stimulation with thrombin. Indeed, thrombin led to an increase in the phosphorylation of AMPK on Thr172 as well as that of its substrate ACC.
Several AMPK phosphorylating kinases or AMPKKs have been described and on the basis of the literature available we initially speculated that CaMKKβ would be essential for the phosphorylation and activation of the AMPK in platelets. Indeed, the thrombin induced activation of the AMPK in endothelial cells depends on the CaMKKβ. 14 However, we found that CaMKK inhibition failed to inhibit thrombin-induced AMPK phosphorylation in platelets although it was effective in endothelial cells. Thrombin-induced activation of the AMPK was however paralleled by the phosphorylation of another kinase, LKB1 suggesting that it may act as an AMPKK under the conditions studied. The consequence of LKB1 phosphorylation for its activity is not clear. Indeed, LKB1 is assumed to be constitutively active and increases in cellular AMP levels were reported to stimulate AMPK activity by decreasing its dephosphorylation by the phosphatase PP2C. 2 In endothelial cells however, stimuli such as fluid shear stress, 23 peroxynitrite 24 and the anti-diabetic drug metformin 25 have all been reported to elicit the phosphorylation and increase the activity of LKB1. Thus, it now seems that phosphorylation does in fact play a role in LKB1 activation. Unfortunately, due to the lack of an appropriate LKB1 inhibitor and the inability to successfully apply small interfering RNA techniques to platelets, we were not able to provide direct evidence for the dependence of AMPK activity on the phosphorylation of LKB1. What are the events upstream of LKB1 phosphorylation? The phosphorylation of LKB1 as well as that of the AMPK were both sensitive to low concentrations of wortmannin indicating the upstream involvement of the PI3-K. Although LKB1 is not known to be a direct substrate of PI3-K, activation of LKB1 by the downstream effector kinase, Akt, may explain the effects observed. Indeed, LKB1 has been shown to be required for the Akt-dependent phosphorylation of pro-apoptotic proteins in a cancer cell line. 26 However, the interaction between AMPK and Akt is both complex and controversial since Akt has been shown to inactivate AMPK in cardiac myocytes, 27;28 while the AMPK has been reported to negatively regulate Akt in breast cancer cells 29 and in endothelial cells exposed to flow. 30 Platelet activation involves several initial steps, which include the release of Ca 2+ followed by the activation of PKC leading to granule secretion, platelet aggregation and integrin αIIbβ3 phosphorylation or "inside-out activation". Thereafter, the active integrin binds fibrinogen and initiates the outside-in signaling which is crucial for clot retraction and thrombus consolidation. 31 The results of the present investigation indicate that the AMPK can influence processes involved in clot retraction. Indeed, although the inhibitors used affect the activity of several kinases, it was possible to show that the pharmacological inhibition of thrombininduced clot retraction and β 3 integrin phosphorylation observed in human platelets was also evident in platelets from AMPKα2 -/-mice. These in vitro observations were supported by the finding that thrombus formation and stability were unaffected by the deletion of the AMPKα1 subunit but altered in AMPKα2 -/-mice in the in vivo model of FeCl 3 -induced carotid artery injury. Taking all of this evidence together it seems safe to conclude that the AMPKα2 subunit appears to be more important than the α1 for the regulation of platelet function.
How could the AMPK affect platelet aggregation and clot retraction? One possibility is via interference with the αIIbβ3 integrin signaling. There is indirect evidence indicating such a link, as iodotubercidin has been reported to inhibit the phosphorylation of β3 integrin (on Thr753). 32 However, attributing the latter effect to the AMPK would be controversial given that phosphorylation was induced by the phosphatase inhibitor calyculin A and a second AMPK inhibitor, 9-β-D-arabinofuranoside, was without effect. In the present study, we observed a clear kinase inhibitor-sensitive tyrosine phosphorylation of β3 integrin in human and murine platelets. Moreover, the thrombin-induced phosphorylation of β3 integrin was clearly inhibited in platelets from AMPKα2 -/-mice. These data indicated that AMPKα2 may modulate platelet function by modulating the activity of a β3 integrin phosphorylating tyrosine kinase. The most likely candidates to mediate the latter effect are the SFKs which are known to be activated by agonists such as thrombin, 33 as well as by oxidative signaling events.
Several of this family of kinases, including Src and Fyn, can be detected in megakaryocytes and platelets and are thought to be involved in regulating platelet function, 21 via binding to distinct sites on the cytoplasmic domain of β3 integrin. 35 Although we saw no evidence for a link between AMPKα2 and Src, we found that AMPKα2 phosphorylated Fyn on Thr12, a residue reported to be associated with kinase activation. 22 In adipocytes, which express predominantly the AMPKα1 isoform, 5 a link between Fyn and AMPK has already been suggested. 36 However, in the latter study Fyn was proposed to act as a negative regulator of AMPK activation; most probably by phosphorylating LKB-1, thus preventing its translocation from the nucleus to the cytoplasm and decreasing AMPK activation. 37 We also observed that Fyn phosphorylated the recombinant AMPKα1 and were unable to detect the phosphorylation of Fyn by AMPKα1 (authors unpublished observation) -findings that are in line with observations made in adipocytes. 38 Moreover, our data also clearly indicate that AMPKα2 rather than AMPKα1 is linked with changes in platelet function, that AMPKα2 is able to phosphorylate Fyn on Thr12, and that the activated Fyn in turn phosphorylates platelet β3 integrin. This sequence of events can account for the attenuated clot retraction in human platelets treated with iodotubercidin or compound C as well as the formation of instable thrombi in the AMPKα2 -/-mice. These observations are certainly of physiological and pathophysiological relevance as the abnormalities in platelet function described in the present study are similar to the platelet phenotype of Fyn-deficient mice. 35 Given that several diseases have been associated with altered AMPK activity (for review see 
